Wave Life Sciences Ltd - Asset Resilience Ratio
Wave Life Sciences Ltd (WVE) has an Asset Resilience Ratio of 13.80% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Wave Life Sciences Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2017)
This chart shows how Wave Life Sciences Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see WVE current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Wave Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore WVE long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $25.04 Million | 13.8% |
| Total Liquid Assets | $25.04 Million | 13.80% |
Asset Resilience Insights
- Moderate Liquidity: Wave Life Sciences Ltd has 13.80% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Wave Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Wave Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Wave Life Sciences Ltd (2015–2017)
The table below shows the annual Asset Resilience Ratio data for Wave Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $181.84 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $164.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $165.42 Million | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more